{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:39:11Z","timestamp":1793637551861,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12325-022-02411-y","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T15:25:48Z","timestamp":1674573948000},"page":"1474-1493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct02607722","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Takashi","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-874X","authenticated-orcid":false,"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-9966","authenticated-orcid":false,"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nukiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"2411_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12931-022-01938-6","volume":"23","author":"Y Kondoh","year":"2022","unstructured":"Kondoh Y, Suda T, Hongo Y, et al. Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respir Res. 2022;23:24.","journal-title":"Respir Res"},{"key":"2411_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","volume":"190","author":"M Natsuizaka","year":"2014","unstructured":"Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190:773\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2411_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","volume":"56","author":"S Homma","year":"2018","unstructured":"Homma S, Bando M, Azuma A, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018;56:268\u201391.","journal-title":"Respir Investig"},{"key":"2411_CR4","doi-asserted-by":"crossref","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44\u2013e68.","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2411_CR5","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"2411_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","volume":"113","author":"L Richeldi","year":"2016","unstructured":"Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS\u00ae trials. Respir Med. 2016;113:74\u20139.","journal-title":"Respir Med"},{"key":"2411_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","volume":"7","author":"B Crestani","year":"2019","unstructured":"Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7:60\u20138.","journal-title":"Lancet Respir Med"},{"key":"2411_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/resp.12960","volume":"22","author":"A Azuma","year":"2017","unstructured":"Azuma A, Taniguchi H, Inoue Y, et al. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: a subgroup analysis of the INPULSIS\u00ae randomized trials. Respirology. 2017;22:750\u20137.","journal-title":"Respirology"},{"key":"2411_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.socscimed.2017.12.005","volume":"210","author":"A Deaton","year":"2018","unstructured":"Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Soc Sci Med. 2018;210:2\u201321.","journal-title":"Soc Sci Med"},{"key":"2411_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000448288","volume":"92","author":"F Bonella","year":"2016","unstructured":"Bonella F, Kreuter M, Hagmeyer L, et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration. 2016;92:98\u2013106.","journal-title":"Respiration"},{"key":"2411_CR11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/resp.13024","volume":"22","author":"JA Galli","year":"2017","unstructured":"Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017;22:1171\u20138.","journal-title":"Respirology"},{"key":"2411_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40169-017-0172-3","volume":"6","author":"H Toellner","year":"2017","unstructured":"Toellner H, Hughes G, Beswick W, et al. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clin Transl Med. 2017;6:41.","journal-title":"Clin Transl Med"},{"key":"2411_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pupt.2018.01.006","volume":"49","author":"A Tzouvelekis","year":"2018","unstructured":"Tzouvelekis A, Karampitsakos T, Kontou M, et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece. Pulm Pharmacol Ther. 2018;49:61\u20136.","journal-title":"Pulm Pharmacol Ther"},{"key":"2411_CR14","doi-asserted-by":"publisher","first-page":"00172","DOI":"10.1183\/23120541.00172-2019","volume":"6","author":"K Antoniou","year":"2020","unstructured":"Antoniou K, Markopoulou K, Tzouvelekis A, et al. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res. 2020;6:00172\u20132019.","journal-title":"ERJ Open Res"},{"key":"2411_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/DDDT.S284819","volume":"15","author":"M Kato","year":"2021","unstructured":"Kato M, Sasaki S, Tateyama M, et al. Clinical significance of continuable treatment with nintedanib over 12 months for idiopathic pulmonary fibrosis in a real-world setting. Drug Des Devel Ther. 2021;15:223\u201330.","journal-title":"Drug Des Devel Ther"},{"key":"2411_CR16","doi-asserted-by":"publisher","first-page":"205031212110233","DOI":"10.1177\/20503121211023357","volume":"9","author":"M Dobashi","year":"2021","unstructured":"Dobashi M, Tanaka H, Taima K, et al. The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: a multicenter retrospective study. SAGE Open Med. 2021;9:20503121211023356.","journal-title":"SAGE Open Med"},{"key":"2411_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12931-018-0907-8","volume":"19","author":"HY Yoon","year":"2018","unstructured":"Yoon HY, Park S, Kim DS, Song JW. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respir Res. 2018;19:203.","journal-title":"Respir Res"},{"key":"2411_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.resinv.2014.08.003","volume":"53","author":"S Homma","year":"2015","unstructured":"Homma S, Sugino K, Sakamoto S. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respir Investig. 2015;53:7\u201312.","journal-title":"Respir Investig"},{"key":"2411_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000397","volume":"6","author":"L Lancaster","year":"2019","unstructured":"Lancaster L, Crestani B, Hernandez P, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6: e000397.","journal-title":"BMJ Open Respir Res"},{"key":"2411_CR20","doi-asserted-by":"publisher","first-page":"10811","DOI":"10.1038\/s41598-017-11321-x","volume":"7","author":"S Ikeda","year":"2017","unstructured":"Ikeda S, Sekine A, Baba T, et al. Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis. Sci Rep. 2017;7:10811.","journal-title":"Sci Rep"},{"key":"2411_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.resinv.2020.08.003","volume":"59","author":"Y Uchida","year":"2021","unstructured":"Uchida Y, Ikeda S, Sekine A, et al. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis. Respir Investig. 2021;59:99\u2013105.","journal-title":"Respir Investig"},{"key":"2411_CR22","first-page":"74","volume":"36","author":"Y Toi","year":"2019","unstructured":"Toi Y, Kimura Y, Domeki Y, et al. Association of low body surface area with dose reduction and\/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36:74\u20138.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2411_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.resinv.2018.12.010","volume":"57","author":"S Ikeda","year":"2019","unstructured":"Ikeda S, Sekine A, Baba T, et al. Low starting-dosage of nintedanib for the reduction of early termination. Respir Investig. 2019;57:282\u20135.","journal-title":"Respir Investig"},{"key":"2411_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/resp.13647","volume":"25","author":"JW Song","year":"2020","unstructured":"Song JW, Ogura T, Inoue Y, et al. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: results from INPULSIS\u00ae-ON. Respirology. 2020;25:410\u20136.","journal-title":"Respirology"},{"key":"2411_CR25","doi-asserted-by":"publisher","first-page":"1702106","DOI":"10.1183\/13993003.02106-2017","volume":"52","author":"I Noth","year":"2018","unstructured":"Noth I, Oelberg D, Kaul M, Conoscenti CS, Raghu G. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. Eur Respir J. 2018;52:1702106.","journal-title":"Eur Respir J"},{"key":"2411_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12890-021-01598-0","volume":"21","author":"U Schmid","year":"2021","unstructured":"Schmid U, Weber B, Sarr C, Freiwald M. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. BMC Pulm Med. 2021;21:244.","journal-title":"BMC Pulm Med"},{"key":"2411_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000495046","volume":"97","author":"E Bendstrup","year":"2019","unstructured":"Bendstrup E, Wuyts W, Alfaro T, et al. Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events. Respiration. 2019;97:173\u201384.","journal-title":"Respiration"},{"key":"2411_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106369","volume":"180","author":"U Schmid","year":"2021","unstructured":"Schmid U, Weber B, Magnusson MO, Freiwald M. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. Respir Med. 2021;180: 106369.","journal-title":"Respir Med"},{"key":"2411_CR29","doi-asserted-by":"crossref","unstructured":"Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group report. Am J Respir Crit Care Med. 2016;194:265\u201375.","DOI":"10.1164\/rccm.201604-0801CI"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02411-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02411-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02411-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:36:49Z","timestamp":1680518209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02411-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2411"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02411-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"18 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}